Pharmaceuticals.jpg

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

231277-92-2

Lapatinib

231277-92-2
103577-45-3

Lansoprazole USP

103577-45-3
138199-71-0

Levofloxacin USP

138199-71-0
132866-11-6

Lercanidipine HCl

132866-11-6
417716-92-8

Lenvatinib

417716-92-8
23672-07-3

Levopride

23672-07-3
75330-75-5

Lovastatin

75330-75-5
14769-73-4

Levamisole

14769-73-4
79-63-0

Lanosterol purity >50%

79-63-0
82186-77-4

Lumefantrine

82186-77-4
4618-18-2

Lactulose

4618-18-2
887769-34-8

Dehydro Lercanidipine

887769-34-8
64044-51-5

Lactose Monohydrate D

64044-51-5
358629-47-7

Dehydro Levetiracetam

358629-47-7
585-86-4

Lactitol

585-86-4
502-65-8

Lycopene

502-65-8
79-54-9

Levopimaric Acid

79-54-9
154-21-2

Lincomycin

154-21-2
727718-93-6

Losartan Azide

727718-93-6
56392-17-7

Metoprolol tartrate

56392-17-7